Is COSCIENS Biopharma Stock a Good Investment?
COSCIENS Biopharma Investment Advice | CSCI |
- Examine COSCIENS Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research COSCIENS Biopharma's leadership team and their track record. Good management can help COSCIENS Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact COSCIENS Biopharma's business and its evolving consumer preferences.
- Compare COSCIENS Biopharma's performance and market position to its competitors. Analyze how COSCIENS Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if COSCIENS Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about COSCIENS Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in COSCIENS Biopharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if COSCIENS Biopharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine COSCIENS Biopharma Stock
Researching COSCIENS Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 0.49. Some equities with similar Price to Book (P/B) outperform the market in the long run. COSCIENS Biopharma recorded a loss per share of 2.69. The entity had not issued any dividends in recent years. The firm had 1:4 split on the 3rd of May 2024.
To determine if COSCIENS Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding COSCIENS Biopharma's research are outlined below:
| COSCIENS Biopharma generated a negative expected return over the last 90 days | |
| COSCIENS Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| COSCIENS Biopharma was previously known as Aeterna Zentaris and was traded on NASDAQ Exchange under the symbol AEZS. | |
| The company reported the previous year's revenue of 7.26 M. Net Loss for the year was (3.55 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| COSCIENS Biopharma generates negative cash flow from operations | |
| Latest headline from globenewswire.com: COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs |
COSCIENS Biopharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.08 M.Evaluate COSCIENS Biopharma's management efficiency
COSCIENS Biopharma has return on total asset (ROA) of (0.2334) % which means that it has lost $0.2334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6592) %, meaning that it created substantial loss on money invested by shareholders. COSCIENS Biopharma's management efficiency ratios could be used to measure how well COSCIENS Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of now, COSCIENS Biopharma's Total Assets are increasing as compared to previous years. The COSCIENS Biopharma's current Total Current Assets is estimated to increase to about 15.6 M, while Non Current Assets Total are projected to decrease to under 14.5 M.COSCIENS Biopharma showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 2.274 |
Basic technical analysis of COSCIENS Stock
As of the 2nd of December, COSCIENS Biopharma shows the risk adjusted performance of (0.05), and Mean Deviation of 2.09. COSCIENS Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Understand COSCIENS Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing COSCIENS Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | 1.91 | |||
| Mean Deviation | 2.09 | |||
| Coefficient Of Variation | (1,249) | |||
| Standard Deviation | 3.04 | |||
| Variance | 9.25 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.76) | |||
| Treynor Ratio | 1.9 | |||
| Maximum Drawdown | 16.83 | |||
| Value At Risk | (5.57) | |||
| Potential Upside | 5.34 | |||
| Skewness | (0.21) | |||
| Kurtosis | 1.98 |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | 1.91 | |||
| Mean Deviation | 2.09 | |||
| Coefficient Of Variation | (1,249) | |||
| Standard Deviation | 3.04 | |||
| Variance | 9.25 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.76) | |||
| Treynor Ratio | 1.9 | |||
| Maximum Drawdown | 16.83 | |||
| Value At Risk | (5.57) | |||
| Potential Upside | 5.34 | |||
| Skewness | (0.21) | |||
| Kurtosis | 1.98 |
Consider COSCIENS Biopharma's intraday indicators
COSCIENS Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of COSCIENS Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 637.09 | |||
| Daily Balance Of Power | (0.72) | |||
| Rate Of Daily Change | 0.93 | |||
| Day Median Price | 3.05 | |||
| Day Typical Price | 3.0 | |||
| Price Action Indicator | (0.23) | |||
| Period Momentum Indicator | (0.21) |
COSCIENS Stock media impact
Far too much social signal, news, headlines, and media speculation about COSCIENS Biopharma that are available to investors today. That information is available publicly through COSCIENS media outlets and privately through word of mouth or via COSCIENS internal channels. However, regardless of the origin, that massive amount of COSCIENS data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of COSCIENS Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of COSCIENS Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to COSCIENS Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive COSCIENS Biopharma alpha.
COSCIENS Biopharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards COSCIENS Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
COSCIENS Biopharma Corporate Executives
Elected by the shareholders, the COSCIENS Biopharma's board of directors comprises two types of representatives: COSCIENS Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of COSCIENS. The board's role is to monitor COSCIENS Biopharma's management team and ensure that shareholders' interests are well served. COSCIENS Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, COSCIENS Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Giuliano Fratta | Senior CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in COSCIENS Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 3.759 | Quarterly Revenue Growth 0.041 | Return On Assets (0.23) | Return On Equity (0.66) |
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between COSCIENS Biopharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.